Latest "Delaware's Partnership to Fight Chronic Disease" News Stories

10:27 EDT 21st June 2018 | BioPortfolio

Here are the most relevant search results for "Delaware's Partnership to Fight Chronic Disease" found in our extensive news archives from over 250 global news sources.

More Information about Delaware's Partnership to Fight Chronic Disease on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Delaware's Partnership to Fight Chronic Disease for you to read. Along with our medical data and news we also list Delaware's Partnership to Fight Chronic Disease Clinical Trials, which are updated daily. BioPortfolio also has a large database of Delaware's Partnership to Fight Chronic Disease Companies for you to search.

Showing "Delaware Partnership Fight Chronic Disease" News Articles 1–25 of 17,000+

Thursday 21st June 2018

Guided Therapeutics Provides Progress Update on International Activities

Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, continues to make progress with commercial activities internationally. 1. China. We are in the process of transferring manufacturing to our commercialization partner in China for the Chinese market. In addition, ...

PrescribeWellness and Thrive Pharmacy Transformations Partner to Create Webinar Series

10-Part Continuing Education Accredited Series Will Support Community Pharmacists in Transforming Their Practices From Pill-Centric to Patient-Centric Model PrescribeWellness, a leading cloud-based patient relationship management solutions company that inspires collaboration between pharmacies, payers, providers, pharmaceutical companies,

Nosopharm Renews its Partnership with Inra

Nosopharm, a company dedicated to the research and development of new anti-infective drugs, announces that it has renewed its partnership with the French National Institute of Agricultural Research (Inra). This partnership with Inra’s Diversity, Genomes and Insects-Microorganisms Interactions laboratory (DGIMI) aims...

PERT Consortium and BTG Form Strategic Partnership

BTG plc (LSE: BTG), the global healthcare company, today announced at the annual PERT ConsortiumTM Meeting in Nashville, TN, a strategic partnership with the PERT ConsortiumTM to advance the science of Pulmonary Embolism (PE) treatment and promote the implementation of PERTTM programs across the U.S. In the United States, pulmonary embolism afflic...

Researcher Zeroes In On The Pre-Clinical Phase Of Alzheimer’s As Way To Stop Disease From Progressing

Reisa Sperling looks at the ten to fifteen year span before the onset of the disease when patients already have build-up of a protein that is believed to trigger the deterioration of the brain. In other public health news: pancreatic cancer, gout, depression, genetic testing, grandchildren for hire, and more.

Standard Process Partners With Genomind To Offer Mindful DNA – A Breakthrough In Personalized Wellness

Standard Process and Genomind have announced a partnership to assist patients with personal wellness. Genomind is the developer of the new genetic test Mindful DNA™, used to help guide lifestyle, diet and nutritional supplement decisions to improve the overall health and wellbeing of patients. PALMYRA, Wis. (PRWEB) June 21, 2018 Standard Process and Genomind have announced a partnership to assi...

Rite Aid Schedules Special Stockholder Meeting for August 9, 2018 to Vote on the Proposed Merger with Albertsons

Rite Aid Corporation (NYSE: RAD) (“Rite Aid”), announced today that it has established a meeting date of August 9, 2018, for a special meeting of stockholders of record as of June 22, 2018 to, among other things, consider and vote on a proposal to approve the previously announced Agreement and Plan of Merger, dated as of February 18, 2018 (the “Merger ...

Incyte to Present Diversified Development Portfolio and Opportunities for Accelerated Growth at 2018 Investor and Analyst Event

Five late-stage oncology product candidates being developed in 15 different indications have the potential to significantly accelerate near-term revenue growth Pivotal REACH1 study of Jakafi® (ruxolitinib) in steroid-refractory acute GVHD met primary endpoint; sNDA submission expected in the third quarter of 2018 ...

MetaStat Presents Positive Data Showing Inhibition of the MENA-pathway Reduces Cancer Cell Dissemination and Paclitaxel Resistance in Aggressive Cancer

Data presented at the AACR Cancer Dormancy and Residual Disease meeting support a novel therapeutic approach to combating the spread of aggressive cancer MetaStat, Inc. (OTCQB: MTST), a precision medicine company developing novel anti-metastatic medications for patients with aggressive cancer, presented positive results from preclinical studies showing...

Appili Therapeutics to Present at 2018 Atlantic Venture Forum Technology Showcase

Appili Therapeutics Inc. (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development, announced today that it will present at the 2018 Atlantic Venture Forum Technology Showcase. The event takes place June 28-29, 2018 in Halifax, Canada. Appili’s Chief Executive Officer Kevin Sullivan will p...

Incyte Announces REACH1 Pivotal Trial Meets Primary Endpoint of Overall Response Rate for Ruxolitinib (Jakafi®) in Steroid-Refractory Acute Graft-Versus-Host Disease

Results support planned sNDA submission in 2018 Incyte Corporation (Nasdaq:INCY) today announced positive topline results from its ongoing pivotal Phase 2 REACH1 trial evaluating ruxolitinib (Jakafi®) in combination with corticosteroids for the treatment of patients with steroid-refractory acute graft-versus-host disease (GVHD). The study met its prim...

Cigna Intensifies Effort to Curtail Opioid Epidemic by Confronting Opioid Addiction and Overdose in U.S. Communities

Goal to reduce opioid overdoses by 25 percent among its customers in targeted communities by year-end 2021 Community-based approach aims to improve access to care and resources for chronic pain and addiction Continues collaboration with doctors and other prescribers to further reduce opioid misuse ...

PhoreMost and o2h discovery collaborate to progress first-in-class drug discovery programs

PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage. This press release features multimedia. Vi...

Biologists discover how pancreatic tumours lead to weight loss

Patients with pancreatic cancer usually experience significant weight loss, which can begin very early in the disease. A new study from MIT and Dana-Farber Cancer Institute offers insight into how this happens, and suggests that the weight loss may not...

Breakthrough discovery reveals brain metals that may drive progression of Alzheimer’s disease

Alzheimer's disease could be better treated, thanks to a breakthrough discovery of the properties of the metals in the brain involved in the progression of the neurodegenerative condition, by an international research collaboration including the University of Warwick.

One Type Of Data Is Not Enough In Personalized Medicine

ArticleThe big challenge in cancer is that each patient's disease is different from a molecular point of view and has a unique set of molecular features that have led to its development, according to researchers.

Clinical data demonstrates significantly increased cure rates using Resistance Guided Therapy for treating the STI Superbug M. genitalium

SpeeDx ResistancePlus® MG test supports new STI management guidelines SYDNEY, Australia, June 21, 2018 (GLOBE NEWSWIRE) -- SpeeDx Pty. Ltd. today announced clinical data contained in a new study published in the June 2018 issue of Clinical Infectious Diseases1 [link] supports the use of Resistance Guided Therapy for more effective treatment of Mycoplasma genitalium infections. Using...

Global Lyme Alliance Surpasses $10 Million Mark in Research Grant Funding

GLA awards nearly $2 million this year alone to leading researchers at prestigious academic and medical institutions across the country. STAMFORD, Conn. (PRWEB) June 21, 2018 As part of its ambitious mission to accelerate Lyme and tick-borne disease research toward better diagnostics, improved treatments and a cure, Global Lyme Alliance (GLA) announced today that it has surpassed the $10 million ...

MaaT Pharma and Lutech Sign Licensing Agreement on Microbiome Therapy for Graft-vs-Host Disease

MaaT Pharma receives world-wide exclusive license to technology co-developed with hematology and gastroenterology departments of Saint-Antoine Hospital, Paris MaaT Pharma, a clinical-stage microbiome therapy company, and SATT Lutech, a private technology transfer company holding the exclusive rights to the scientific findings from research groups at So...

CellGenix Completed First Step of Facility Expansion to Stay on Top of the Increasing Demands for GMP Cell Culture Reagents

Freiburg, Germany, June 21, 2018 / B3C newswire / -- CellGenix, a global manufacturing leader of GMP-grade raw materials for cell therapy, gene therapy and tissue-engineered products, successfully completed the first phase of its headquarters’ expansion as more customers approach late-stage clinical development and commercialization. In a first step, the company added additional space to its he...

Long-term DBS Linked to Less Psychosis, Falls in Parkinson's

Ten-year follow-up of patients with Parkinson's disease who underwent subthalamic deep-brain stimulation (DBS) shows they had lower risk for psychosis and falls than those not receiving DBS. Medscape Medical News

50% of Patients With PD on DAs Develop Impulse Disorders

Almost half of patients with Parkinson's disease who take dopamine agonists develop impulse control disorders at 5 years, a large longitudinal study shows. Medscape Medical News

Aquinnah Pharmaceuticals receives $3.4 million grant to advance ALS therapies

Aquinnah Pharmaceuticals has announced that it has been awarded a $3.4 million grant from the National Institute of Neurological Disorders and Stroke (NINDS) to advance novel therapeutic drug candidates towards the clinic for treating patients with the neurodegenerative disease, amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. read more

Achieve TMS, Nation’s Largest Deep TMS Provider for Depression Opening New Center in Jantzen Beach, OR

TMS Treatment Provides Relief from Depression -- and Mental Wellness -- Often without Meds PORTLAND, Ore. (PRWEB) June 21, 2018 Achieve TMS, the nation’s largest and most experienced provider of deep Transcranial Magnetic Stimulation (dTMS) is opening a state-of-the-art treatment center in Jantzen Beach, OR on July 1 to treat patients suffering from depression. The center will serve patients in...

Addex Shareholders Approve All Resolutions at Annual General Meeting

Addex Therapeutics / Addex Shareholders Approve All Resolutions at Annual General Meeting . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. Geneva, Switzerland, 21 June 2018 - Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announc...

Quick Search


News Quicklinks